Activating mutations of FGFR3 are a common and early event in bladder cancer. Ectopic expression of mutant FGFR3 in normal urothelial cells has both pro-proliferative and antiapoptotic effects at confluence, suggesting that mutant cells are insensitive to cell-cell contact inhibition. Herein, detailed analysis revealed that these cells have reduced cell-cell adhesion, with large intercellular spaces observable at confluence, and diminished cell-substrate adhesion to collagen IV, collagen I, and fibronectin. These phenotypic alterations are accompanied by changes in the expression of genes involved in cell adhesion and extracellular matrix remodeling. Silencing of endogenous mutant FGFR3 in bladder cancer cells induced converse changes in transcript levels of CDH16, PLAU, MMP10, EPCAM, TNC, and HAS3, confirming them as downstream gene targets of mutant FGFR3. Overexpression of EPCAM, HAS3, and MMP10 transcripts was found in a large fraction of primary bladder tumors analyzed, supporting their key role in bladder tumorigenesis in vivo. However, no correlation was found between their protein and/or mRNA expression and FGFR3 mutation status in tumor specimens, indicating that these genes may be targeted by several converging oncogenic pathways. Overall, these results indicate that mutant FGFR3 favors the development and progression of premalignant bladder lesions by altering key genes regulating the cell-cell and cell-matrix adhesive properties of urothelial cells.
Introduction
FGFR3 is one of four transmembrane tyrosine-kinase receptors mediating the cellular effects of FGFs. Binding of FGFs to the extracellular portion of FGFR3 induces its dimerization, followed by phosphorylation of its cytoplasmic tyrosine kinase domain and activation of a number of downstream signaling pathways regulating a range of cellular functions (1) .
Activating mutations of FGFR3 are a common finding in urothelial carcinoma of the bladder, particularly in the subset of low-grade and low-stage tumors, where their frequency reaches 70% (2) . They map to three mutation hotspots in exons 7 (codons 248 and 249), 10 (codons 372, 373, 375, 382, and 393) and 15 (codon 653) (3) . Mutations in exons 7 and 10 produce an unpaired cysteine residue in the extracellular domain, inducing the formation of disulfide bonds between adjacent monomers, and therefore receptor dimerization and activation in the absence of ligand (4, 5) . These are the most frequent of all FGFR3 mutations observed in bladder tumors and include S249C ($61%), Y375C ($19%), R248C ($8%), and G372C ($6%) (3) . Mutations in exon 15 cause a conformational change in the regulatory region of the receptor, leading to constitutive phosphorylation and activation (6) . These mutations involve codon 652 and are rarer in bladder tumors (<2% of mutant tumors). Other mutations of the hotspot regions are only found in a very small proportion of cases (<5%) (3) . Besides bladder cancer, activating mutations of FGFR3 are also detected in benign skin tumors (7) and, at lower frequency, in multiple myeloma (8) and cervical cancer (9) .
FGFR3 mutations are thought to be an early change during urothelial transformation, as they are often detected in flat urothelial hyperplasia, a proposed precursor lesion for urothelial carcinoma (10) . Interestingly, a number of bladder tumors without FGFR3 mutation display overexpression of wild-type FGFR3 as an alternative mechanism of FGFR3 upregulation (11) . Therefore, overall a very high proportion of bladder tumors are characterized by FGFR3 dysregulation. In vitro studies have shown that silencing or inhibition of FGFR3 in bladder cancer cells is associated with decreased proliferation, reduced anchorage-independent growth, and enhanced apoptosis (12) (13) (14) , and FGFR inhibitors have therefore been proposed as novel therapeutic agents in the treatment of bladder tumors (15) . However, little is known about the detailed molecular mechanism by which FGFR3 signaling contributes to the malignant transformation of urothelial cells.
We have shown that expression of ectopic mutant FGFR3 in normal urothelial cells (NHUC) induces aberrant activation of the MAPK and PLCg1 signaling pathways and increases cell proliferation and viability at confluence (16) . As a result, NHUC expressing mutant FGFR3 have an increased saturation density, reaching higher cell numbers in confluent conditions compared with control cells. The intensity of the phenotypic effect is mutation dependent and reflects the relative mutation frequencies observed in bladder tumors (16) . On the basis of these results, we hypothesized that mutant FGFR3 may allow urothelial cells to escape cell-cell contact inhibition and therefore contribute to the development of hyperplastic lesions in the bladder.
In this study, we investigate the consequences of FGFR3 mutation on the adhesive properties of urothelial cells. We show that normal urothelial cells expressing ectopic mutant FGFR3 display reduced cell-cell and cell-substrate adhesion and identify a number of FGFR3 target genes that could be mediating this phenotype in vitro. Overall, our data provide a deeper understanding of the oncogenic effects of mutant FGFR3 by indicating molecular mechanisms by which it may drive the development of bladder tumors.
Materials and Methods

Cell lines
Normal urothelial cells immortalized with telomerase (TERT-NHUC) and expressing mutant FGFR3 were obtained as described previously (16) . Expression of endogenous S249C FGFR3 was silenced in the bladder cancer cell line 97-7 using shRNA, as described previously (13) . Cell lines were cultured in standard growth media at 37 C in 5% CO 2 . Cell line identity was verified by short tandem repeat DNA typing using a Powerplex 16 kit (Promega). Profiles were compared with matched initial patient samples (TERT-NHUC) and profiles obtained from early passage cells from the originating laboratory (97-7).
Tumor samples
Bladder tumor samples classified according to World Health Organization and Tumor-Node-Metastasis guidelines were collected in Leeds (UK) between 2001 and 2004, with ethical approval and written informed consent (Leeds East 99/156). RNA, DNA, and formalin-fixed and paraffin-embedded (FFPE) tissue were obtained as described previously (17) . Representative fresh-frozen sections were stained with hematoxylin and examined to determine tumor content. Only samples containing >70% tumor material were included in the study. FGFR3 mutation status was assessed by SNaPshot or high-resolution melting curve analysis followed by sequencing, as described previously (18, 19) . The mRNA analysis included a total of 44 tumors of all grades and stages. Information about grade, stage, and FGFR3 status is summarized in Supplementary Table S1 . Protein analysis included a total of 48 pTaG2 tumors, of which 34 were mutant for FGFR3 (26 S249C, 3 G372C, 2 Y375C, 2 R248C, 1 K652E) and 14 were wild type.
Immunofluorescence
Cells were seeded on glass coverslips and grown to confluence. Cells were then fixed with 4% paraformaldehyde for 10 minutes at 4 C, permeabilized with 0.1% Triton X-100 (Sigma-Aldrich Company Ltd.), and incubated with 1 mg/mL DAPI, 1:500 mouse monoclonal anti-E-cadherin antibody (HECD-1; Abcam Plc.), and 1:500 rabbit polyclonal anti-b-catenin antibody (SigmaAldrich Company Ltd.) for 1 hour at room temperature. E-cadherin and b-catenin localization was detected by fluorescence microscopy using 1:300 Alexa Fluor 488 goat anti-mouse and Alexa Fluor 594 goat anti-rabbit IgGs (Life Technologies Ltd).
Cell-substrate detachment assays
To test cell-substrate detachment, cells were grown to high confluence in 6-well plates coated with different substrates (BD Biosciences). Cells were then subjected to trypsinization by incubating for 12 minutes with Trypsin-EDTA solution (0.5 g/L porcine trypsin and 0.2 g/L EDTA; Sigma-Aldrich Company Ltd.). For qualitative results, attached cells were fixed and stained with 1% methylene blue in 50% ethanol; for quantitative results, both detached and attached cells were counted with a Z2 Coulter analyzer (Beckman Coulter Ltd.).
RNA extraction and microarray processing
RNA from cell lines was extracted using TRIzol reagent (Life Technologies Ltd), following the manufacturer's instructions. RNA was DNAse treated and repurified using the RNeasy mini Kit (Qiagen Ltd.). RNA from snap-frozen tumor tissue was extracted with the RNeasy mini Kit (Qiagen Ltd.), including the optional DNAse treatment step. For expression array analysis, RNA labeling and hybridization were performed by the Cancer Research UK Manchester Institute Microarray Service. Briefly, 2 mg of total RNA was used to prepare biotinylated target cRNA, according to the Affymetrix One Cycle Target Preparation Protocol, which was then hybridized on Affymetrix HG U133 Plus 2.0 oligonucleotide arrays (Affymetrix UK Ltd.). These data are available in the GEO NCBI database (accession no. GSE61352).
Expression array analysis
Expression array data were analyzed using R (http://www.Rproject.org) and Bioconductor (20) . They were processed at the probe level using the RMA algorithm (21) , and the difference between NHUC expressing ectopic S249C FGFR3 and control NHUC containing the empty vector was tested using moderated t tests, where the variances were estimated using an empirical Bayes method to correct for underestimation of noise (22) . To control for false discovery rate (FDR) due to multiple testing effects, the P values were adjusted using the Benjamini-Hochberg method. A threshold of 1% FDR was employed to determine differential expression. Genes involved in cell-cell and cell-substrate adhesion were highlighted within the differentially expressed genes using the Ingenuity Pathway analysis 7.6 software (Ingenuity Systems Inc.), the publicly available DAVID Bioinformatics database (23) , and a literature search.
Real-time RT-PCR
cDNA synthesis and Taqman RealTime PCR were performed as described previously (17) . The following TaqMan Gene Expression Assays (Applied Biosystems) were used: Hs00188166_m1 (SDHA, internal control), Hs01013953_ m1 (CDH1), Hs00901888_g1 (EPCAM), Hs00355084_ m1 (DSG1), Hs00951428_m1 (DSC2), Hs00187880_m1 (CDH16), Hs00193436_m1 (HAS3), Hs01547054_m1 (PLAU), Hs00938315_m1 (PLAT), Hs00169627_m1 (CD36), Hs00233987_m1 (MMP10), and Hs01115665_m1 (TNC). Gene expression was normalized to SDHA using the DC t method and quantified relative to a positive control sample. Nontemplate negative controls were included in each plate.
Immunohistochemistry
Immunohistochemistry was performed as described previously (17) . Samples were incubated with 1:400 mouse anti-EPCAM (C-10; Santa Cruz Biotechnology Inc.) or 1:400 goat anti-HAS3 (E15; Santa Cruz Biotechnology Inc.). Incubation with primary antibody was performed either for 1 hour at room temperature (EPCAM), or 4 C overnight (HAS3). Scoring was performed independently by three investigators (J.-A. Roulson, M.A. Knowles, and E. di Martino). Samples stained for EPCAM were scored for percentage of positive cells, and for staining intensity across the whole tumor, quantified using the following arbitrary units:
For each sample, a staining score was calculated as staining intensity Â % positive cells, and an average staining score calculated for each sample. Because of generally weak staining and heterogeneity across the tissue, tumors stained for HAS3 were only scored for overall expression in relation to normal bladder tissue (positive ¼ expression above control, negative ¼ expression equal or below control).
Statistical analysis
Significant differences in gene expression between tumors stratified according to stage, grade, and FGFR3 mutation status were assessed using the Mann-Whitney test, with the SPSS 12.0 statistical analysis software (SPSS Inc.). P 0.05 was accepted as significant.
Results
Mutant FGFR3 alters cell-cell adhesion of normal urothelial cells
Our previous results suggested that telomerase-immortalized normal human urothelial cells (TERT-NHUC) expressing ectopic mutant FGFR3 may lack cell-cell contact inhibition. Thus, we investigated the cell-cell and cell-substrate adhesive properties of FGFR3-mutant TERT-NHUC in more detail. We stained normal and mutant FGFR3-expressing cells for E-cadherin and b-catenin. This highlighted some morphologic changes in cells expressing S249C-mutant FGFR3. Although control cells and cells expressing wild-type FGFR3 formed a tight monolayer, cells expressing S249C-FGFR3 displayed looser cell-cell junctions and increased intercellular spaces (Fig. 1A) . It has been shown that FGFR1 can bind to E-cadherin, and this interaction is followed by their co-endocytosis and E-cadherin delocalization to the cytoplasm (24) . However, no differences in the localization or level of Ecadherin or b-catenin were observed between control and S249C-FGFR3-expressing TERT-NHUC. Western blotting of fractioned membrane and cytoplasmic protein extract confirmed that in both control and S249C-FGFR3 cells E-cadherin was localized mainly in the membrane compartment (data not shown). Furthermore, we could not demonstrate any interaction between Ecadherin and mutant FGFR3 in TERT-NHUC by protein coimmunoprecipitation and Western Blotting (data not shown). Taken together, these results suggest that some other molecular mechanisms may mediate the effects of mutant FGFR3 on cell-cell contact.
Mutant FGFR3 alters cell-substrate adhesion of normal urothelial cells
The ability of cells expressing mutant FGFR3 to detach from the substrate was also tested. Confluent cells were subjected to controlled trypsinization to promote their detachment from standard culture dishes and culture dishes coated with various extracellular matrix (ECM) proteins. For qualitative results, detached cells were gently washed away and attached cells were visualized by staining with methylene blue; for quantitative results, both detached and attached cells were counted. A higher number of control cells and cells expressing wild-type FGFR3 remained attached to standard culture dishes compared with cells expressing mutant FGFR3 (P ¼ 0.037; Fig. 1B and C) . The effect was greater in cells expressing the S249C-and Y375C-mutant proteins compared with K652E-FGFR3, in accordance with our previous results that indicated a stronger phenotypic effect for these two mutations (16) . Furthermore, cells expressing S249C-FGFR3 detached more easily from collagen IV, collagen I, and fibronectin, compared with control cells (P ¼ 0.05), whereas no difference was observed in detachment from laminin (Fig. 1D) . Overall, these results suggest that FGFR3 mutation may disrupt the cell-substrate adhesive properties of urothelial cells.
Mutant FGFR3 dysregulates genes involved in cell adhesion and ECM remodeling in normal urothelial cells
To identify molecular targets of mutant FGFR3 which could be modulating the observed changes in cell-cell and cell-substrate adhesion, the gene expression profiles of confluent TERT-NHUCexpressing S249C FGFR3 and control cells containing the empty vector were compared using Affymetrix Human Genome U133 Plus 2.0 arrays. In total, 750 probe sets corresponding to 576 specific genes were significantly up-or downregulated above a 2-fold threshold in mutant cells. Of these, 72 (12.5%) were linked to cell-cell or cell-matrix adhesion (Table 1) , including genes encoding structural proteins of desmosomes (DSC2, DSC3, DSG1, PKP1, and PKP3), adherens junctions (CDH1, CDH16, and EPCAM), and focal adhesions (PXN, ZYX). Mutant FGFR3-expressing cells also exhibited changes in their integrin expression profiles (ITGAV, ITGA2, ITGB5, and ITGB6) and in genes modulating cell-substrate adhesion and ECM remodeling (TNC, CD36, PLAU, PLAT, MMP10). On the basis of magnitude of change in gene expression level, biologic function, evidence of involvement in bladder or other cancers, and availability of validated antibodies for immunohistochemistry, 11 of these genes were chosen for validation and further investigation: DSG1, DSC2, EPCAM, CDH1, CDH16, CD36, MMP10, HAS3, PLAU, PLAT, and TNC.
Downregulation of DSG1, DSC2, CDH16, and CD36 and upregulation of EPCAM, PLAU, PLAT, MMP10, and HAS3 were confirmed by Taqman RealTime RT-PCR in TERT-NHUC expressing mutant FGFR3 compared with control cells (Fig. 2) , whereas no significant downregulation of CDH1 was detected (data not shown). Expression of TNC was higher in cells expressing mutant FGFR3 although some variability was observed between experimental replicates (Fig. 2) . Changes in expression were generally stronger in cells expressing S249C-FGFR3 than in cells expressing K652E-FGFR3, consistent with the previously observed mutationdependent intensity of the phenotypic effects of mutant FGFR3.
Mutant FGFR3 regulates EPCAM, PLAU, TNC, MMP10, HAS3, and CDH16 expression in the bladder cancer line, 97-7
We then investigated whether converse changes in the expression of these genes could be induced by shRNA silencing of FGFR3 in the bladder cancer cell line 97-7, which contains an endogenous S249C mutation. Indeed, silencing of mutant FGFR3 was accompanied by downregulation of EPCAM, PLAU, TNC, MMP10, HAS3 and upregulation of CDH16, and these changes were reversed upon reexpression of S249C-FGFR3 (Fig. 3) . However, DSG1, DSC2, CD36, and PLAT did not show the expected changes in expression after modulation of FGFR3 in these cells (data not shown). Overall, these results confirm that mutant FGFR3 modulates the expression of EPCAM, PLAU, TNC, MMP10, HAS3, and CDH16 in bladder cancer cells.
EPCAM, MMP10, HAS3, TNC, and CDH16 mRNA expression in bladder tumors in relation to FGFR3 mutation To assess whether mutant FGFR3 regulates EPCAM, HAS3, MMP10, TNC, and CDH16 in vivo, we examined the mRNA expression of these genes in a panel of 44 bladder tumors with known FGFR3 mutation status and in normal uncultured urothelium (Fig. 4) . Of 44 tumors, 23 (52%) showed upregulation and 6 (14%) downregulation of EPCAM (>2-fold; Fig. 4A ). HAS3 was overexpressed in 15 of 44 tumors (34%) and downregulated in 7 of 44 (16%; Fig. 4B ). MMP10 was expressed at very low levels in normal urothelium and it was strongly upregulated in 30 of 44 (68%) tumors (Fig. 4C) . TNC expression was not detectable in normal urothelium and therefore a tumor/normal ratio could not be calculated. However, expression of TNC was detected in 18 of 40 (45%) tumors tested, showing that TNC is often upregulated in bladder tumors. No HAS3, MMP10, or TNC expression was detected in 1, 14, and 22 tumors, respectively. However, this could have been the result of low RNA concentration; therefore, expression in these patients was considered inconclusive. CDH16 mRNA was not detected in uncultured normal urothelial cells, normal bladder tissue, or tumors with the assay used.
No statistical difference in expression of HAS3, TNC, or MMP10 was observed when samples were stratified for tumor grade, stage, or FGFR3 mutation status (P > 0.05). No difference in expression of EPCAM was observed in relation to tumor grade and FGFR3 mutation, but a significant difference was observed in relation to tumor stage, with nonmuscle invasive (Ta-T1) tumors showing an average expression significantly lower than muscle invasive tumors (T2 or higher; P ¼ 0.033), consistent with previous reports Ã , significant (P 0.05) differences from control. (25) . Expression of TNC could not be examined in relation to FGFR3 mutation, tumor stage, and tumor grade due to the small number of positive tumors (n ¼ 18).
EPCAM and HAS3 protein expression in low-stage bladder tumors in relation to FGFR3 mutation status
We hypothesized that the lack of correlation between FGFR3 mutation status and the mRNA level of its target genes could be due to the clinical heterogeneity of the group of tumors analyzed, the presence of contaminating tissue, and/or the presence of different subpopulations of cells within the same tumor. Thus, we used immunohistochemistry to gain a more detailed picture of protein expression across different cell types and different areas in 48 tumors of similar grade and stage (pTaG2; n ¼ 34 FGFR3 mutant, and n ¼ 14 FGFR3 wild type) to assess whether a correlation could be found between mutation status and HAS3, MMP10, and EPCAM at the protein level.
EPCAM staining in normal bladder was membranous, of weak to moderate intensity, and mainly localized in lower layers of the epithelium (Supplementary Fig. S1A ). Surface cells were mostly negative, and only occasionally was surface positivity observed. Most tumors showed weak to strong membrane staining, strongest within the lower third of the epithelium but focally extending to the surface (Supplementary Fig. S1B ). Some tumors, however, showed staining throughout ( Supplementary Fig. S1C ). The number of positive cells varied from 10% to 90% with a mean of around 50%. The mean average score was higher in wild-type compared with mutant tumors, but the result did not reach statistical significance (P ¼ 0.106). Interestingly, a small number of samples known to be HRAS or KRAS mutant showed a trend toward highest EPCAM staining, although differences were not significant (P ¼ 0.156).
In normal bladder, we detected a spotty membranous HAS3 staining ( Supplementary Fig. S1D ), consistent with previous results in epithelial cells (26) . The signal was mainly localized to the apical cells, and was of moderate intensity. Only 1% to 10% of other cells showed weak to moderate staining in normal bladder. Staining intensity in tumors varied from weak to strong, and it was very heterogeneous across individual tumors. Only 7 of 48 tumors (14%) showed increased expression compared with normal bladder, and due to the small numbers, correlation between HAS3 upregulation and FGFR3 mutation could not be assessed. However, in contrast with normal bladder, a high proportion of tumors tended to show expression throughout, and not limited to apical cells (Supplementary Fig. S1E and S1F) .
MMP10 immunohistochemistry was performed as described previously (27) . However, staining appeared artifactual in our hands. Attempts to optimize staining by altering antigen retrieval and detection methods, primary antibody concentration, and temperature and length of primary antibody incubation failed to produce satisfactory staining. Therefore, MMP10 immunohistochemistry had to be abandoned. 
Discussion
Although mutant FGFR3 plays an undisputed role in bladder carcinogenesis, little is known of the molecular mechanisms through which FGFR3 signaling contributes to urothelial transformation. Our previous results suggested a possible role in disrupting contact-mediated inhibition of urothelial cell proliferation, thereby favoring the development of hyperplastic lesions in the bladder (16) .
In this study, we used isogenic cell lines as simple in vitro models to unravel phenotypic outcomes of mutant FGFR3 expression and identify downstream effectors and targets. Comparison of normal urothelial cells with and without ectopic expression of mutant FGFR3 highlighted morphologic and gene expression changes suggestive of decreased cell-cell adhesion. Disruption of cell-cell adhesion in bladder and other cancers is often due to alteration in the expression or localization of E-cadherin and b-catenin (28), but no such changes were observed in our model. However, we detected dysregulation of genes encoding other proteins involved in the maintenance of adherens junctions, such as EPCAM and CDH16. CDH16 encodes a kidneyspecific cadherin downregulated in renal neoplasms (29) . Its expression was detected at relatively high levels in normal urothelial cells in vitro and was downregulated upon expression of ectopic mutant FGFR3. However, this gene was not expressed in uncultured urothelial cells or normal bladder tissue, suggesting that although mutant FGFR3 can downregulate this gene under cell culture conditions, this event is unlikely to play a crucial role Reduction of cell-cell adhesion following expression of mutant FGFR3 was also accompanied by decreased cell adhesion to ECM ligands, such as collagen IV, collagen I, and fibronectin, which are normally found in the urothelial basement membrane and connective tissue of the bladder (30) , and by consistent changes in the expression of genes involved in cell-substrate adhesion and ECM remodeling, such as downregulation of CD36, and upregulation of TNC, MMP10, PLAU, and PLAT. Interaction between ECM components and the integrins expressed on the surface of urothelial cells is essential for preserving bladder wall integrity. Indeed, degradation of laminin and collagen IV is associated with the disruption of basement membrane continuity observed in transitional cell carcinomas and is linked to poorer prognosis (31) .
An interesting observation was the upregulation of HAS3 in mutant FGFR3-expressing cells. This is consistent with previous reports that FGFs may induce HAS3 expression in some cell types (32, 33) . HAS3 encodes hyaluronan synthase 3, one of three transmembrane enzymes that mediate synthesis of hyaluronan (HA), a glycosaminoglycan component of the ECM that promotes tumor growth and spreading (34) . HA and HAS1 are upregulated in bladder cancer tissue (35) , and HAS2 knockdown in a bladder cancer cell line was shown to affect proliferation and invasion (36) . Interestingly, HAS3 overexpression in rat fibroblasts was shown to halt cell-cell contact inhibition of proliferation and increase their saturation density (37), similar to the phenotype mediated by mutant FGFR3 in urothelial cells (16) .
Taken together, the results in our in vitro model system suggest that mutation of FGFR3 in normal urothelial cells can favor some of the key steps necessary for tumors to acquire malignant potential and spread. In nonmuscle invasive bladder tumors where FGFR3 mutation is most common, this may allow intraepithelial spread and development of exophytic tumors. Accumulation of other molecular changes is likely to be required for these tumors to acquire a muscle-invasive and metastatic phenotype.
Many of the genes highlighted in this study were previously found to be upregulated in a number of malignancies including bladder tumors (25, 27, (38) (39) (40) , but their relation with mutated FGFR3 had not been tested. Interestingly, however, higher levels of MMP10 have been detected in superficial bladder tumors (27) , which are the subgroup with most frequent FGFR3 mutation (2). We tested whether a correlation between mutant FGFR3 and the expression of some of these genes could also be observed in tumor tissues in vivo. To narrow down the number of genes to investigate in tumor tissues, we further validated their role as downstream transcriptional targets of FGFR3 signaling by testing whether silencing of endogenous mutant FGFR3 in the tumor cell line 97-7 caused converse changes in their expression. MMP10, TNC, HAS3, and EPCAM were confirmed as FGFR3 targets in this second in vitro model. However, although their mRNA and/or protein levels were upregulated in a high proportion of specimens, confirming an important role in bladder malignant transformation, we found no correlation with FGFR3 mutation status in tumor samples. Although we cannot exclude that changes in these genes in response to FGFR3 mutation only occur under cell culture conditions, this lack of correlation may be due to the fact that several distinct carcinogenic pathways may lead to the dysregulation of these genes in tumor tissue, and their expression may be influenced by other genetic and epigenetic events in bladder tumors. All of these may have acted as confounding factors preventing us from detecting a direct correlation between the expression of FGFR3 target genes and FGFR3 mutation status in vivo. Furthermore, FGFR3 overexpression or FGFR3 gene fusions are alternative mechanisms of FGFR3 dysregulation in bladder tumors (11, 41) . Consequently, some of the tumors classified as wild type in this study may have displayed high levels of FGFR3 target genes due to FGFR3 dysregulation through other mechanisms. These results suggest that our in vitro model based on isogenic cell lines is a simpler and more controlled environment allowing the unraveling of molecular changes associated with a single oncogenic event such as FGFR3 mutation. Using this model, it will now be possible to interrogate the role of specific FGFR3-modulated genes in determining phenotype. Of particular interest will be whether there is a regulatory hierarchy within the cell adhesion-related genes identified or whether all are co-ordinately regulated.
In conclusion, we have shown that mutant FGFR3 alters the expression of cell-cell and cell-substrate adhesion genes in two distinct in vitro models. Further studies are required to confirm this oncogenic mechanism in vivo. Overall, this investigation helps to clarify the role of mutant FGFR3 in the development of bladder cancer.
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